Peptide Record

Bremelanotide · full corpus

Explore

Every evidence record, mention, review and regulatory filing collected for Bremelanotide, in one list. Each row links to the original. Nothing here is summarised for you — this is the corpus, source tag by source tag.

219 records · ordered by source hierarchy — human trials first, vendor material last

Corpus records for Bremelanotide
SourceKindRecordAttributionDetailDate
PRECLINICALevidenceFemale Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.BremelanotideSexual function & libido2026-01-01
PRECLINICALevidencePractical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.BremelanotideSexual function & libido2025-10-01
PRECLINICALevidencePolymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.Bremelanotide2025-09-16
PRECLINICALevidence2024 SOGC, 2024 NCCN, 2022 ESO-ESMO, and 2018 ASCO: a comparison of female cancer survivorship guidelines for the management of sexual health concerns.BremelanotideSexual function & libido2025-06-15
PRECLINICALevidenceIntravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions.PT 1412025-04-01
PRECLINICALevidenceNovel Pharmacologic Treatments of Female Sexual Dysfunction.BremelanotideSexual function & libido2025-03-01
PRECLINICALevidencePharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women.BremelanotideSexual function & libido2025-02-01
PRECLINICALevidenceFDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.Bremelanotide2025-01-01
PRECLINICALevidenceMelanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.Bremelanotidepreclinical2024-09-01
PRECLINICALevidenceUnderstanding the Interplay Between Premenstrual Dysphoric Disorder (PMDD) and Female Sexual Dysfunction (FSD).Bremelanotide2024-06-01
PRECLINICALevidenceSmall Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.BremelanotideSexual function & libido2024-05-01
PRECLINICALevidenceA Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022).Bremelanotide2024-03-01
PRECLINICALevidenceWhat Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder.BremelanotideSexual function & libido2024-01-01
PRECLINICALevidenceFirst-time orgasm in a young man with lifelong anorgasmia after flibanserin use: a case report.Bremelanotide2023-12-01
PRECLINICALevidenceUnderstanding Hypoactive Sexual Desire Disorder (HSDD) in Women: Etiology, Diagnosis, and Treatment.Bremelanotide2023-11-01
PRECLINICALevidenceTargeting the central melanocortin system for the treatment of metabolic disorders.Bremelanotide2023-09-01
PRECLINICALevidenceExpression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study.Bremelanotide2023-01-10
PRECLINICALevidencePharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?BremelanotideSexual function & libido2023-01-01
PRECLINICALevidenceAn evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.VyleesiSexual function & libido2023-01-01
PRECLINICALevidencePharmacologic therapeutic options for sexual dysfunction.BremelanotideSexual function & libido2022-12-01
PRECLINICALevidenceLigands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin.BremelanotidePigmentation2022-10-01
PRECLINICALevidenceFinding Our Way From the Bench to the Bedside: The Ethos, Logos, and Pathos of Biomedical Research.Bremelanotide2022-07-01
PRECLINICALevidenceThe neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.BremelanotideSexual function & libido2022-06-01
PRECLINICALevidenceFemale sexual dysfunctions: an overview on the available therapeutic interventions.BremelanotideSexual function & libido2022-06-01
PRECLINICALevidenceManagement of Hypertension with Female Sexual Dysfunction.Bremelanotide2022-05-05
PRECLINICALevidenceMedical Treatment of Female Sexual Dysfunction.BremelanotideSexual function & libido2022-05-01
PRECLINICALevidencePharmacotherapy for Sexual Dysfunction in Women.BremelanotideSexual function & libido2022-02-01
PRECLINICALevidenceBremelanotide for Treatment of Female Hypoactive Sexual Desire.Bremelanotide2022-01-04
PRECLINICALevidenceBremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent.VyleesiSexual function & libido2021-12-01
PRECLINICALevidenceRe-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.BremelanotideSexual function & libido2021-11-01
PRECLINICALevidenceFailure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".BremelanotideSexual function & libido2021-11-01
PRECLINICALevidenceStructural insights into ligand recognition and activation of the melanocortin-4 receptor.VyleesiWeight & fat loss · preclinical2021-11-01
PRECLINICALevidenceHypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.BremelanotideSexual function & libido2021-11-01
PRECLINICALevidencePsychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm.Bremelanotide2021-09-24
PRECLINICALevidenceLC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs.Bremelanotide2021-04-01
PRECLINICALevidenceManagement of hypoactive sexual desire disorder in transgender women: a guide for clinicians.BremelanotideSexual function & libido2020-11-01
PRECLINICALevidenceReliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder.Bremelanotide2020-10-08
PRECLINICALevidenceFemale Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.BremelanotideSexual function & libido2020-08-01
PRECLINICALevidenceBremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.VyleesiSexual function & libido2020-07-01
PRECLINICALevidenceNew Drugs 2020, part 2.Bremelanotide2020-05-01
PRECLINICALevidence2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.Bremelanotide2020-03-05
PRECLINICALevidenceLong-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.BremelanotideSexual function & libido2019-11-01
PRECLINICALevidenceBoosting Female Sexual Response by RECONNECTing the Dots.BremelanotideSexual function & libido2019-11-01
PRECLINICALevidenceNew Drug for Hypoactive Sexual Desire Disorder in Premenopausal Women.BremelanotideSexual function & libido2019-10-01
PRECLINICALevidenceBremelanotide: First Approval.VyleesiSexual function & libido2019-09-01
PRECLINICALevidenceBremelanotide (Vyleesi) for hypoactive sexual desire disorder.VyleesiSexual function & libido2019-07-29
PRECLINICALevidenceWhat are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?Bremelanotide2019-05-01
PRECLINICALevidenceExpert opinion on existing and developing drugs to treat female sexual dysfunction.BremelanotideSexual function & libido2018-09-01
PRECLINICALevidenceFemale Sexual Dysfunction and the Placebo Effect: A Meta-analysis.BremelanotideSexual function & libido2018-08-01
PRECLINICALevidenceEffect Size in Efficacy Trials of Women With Decreased Sexual Desire.BremelanotideSexual function & libido2018-07-01